US based SentreHEART has secured $26m in Series C financing led by Vivo Ventures.

Venture Partners and Prospect Ventures who are existing investors of SentreHEART have also joined the financing round.

The company will use the proceeds to support commercialization activities of Lariat Suture Delivery Device.

The Lariat Suture Delivery Device facilitates clinicians to close the surgical site with a soft tissues by using pre-tied polyester suture.

SentreHEART president and chief executive officer Paul Buckman said, "The LARIAT Suture Delivery Device has the potential to transform certain open surgical procedures traditionally performed in the operating room into more cost effective procedures that can be performed in the catheterization lab, where only a small piece of suture is left behind."